Background: According to epidemiological data, patients with both hypertension (HTN) and
dyslipidemia (DYS) often fail to achieve goals for both conditions, despite their increased …

Hypertension (HTN) and dyslipidemia (DYS) commonly coexist. Patients with concurrent
HTN and DYS are at high risk of cardiovascular disease, yet most patients do not achieve …

The AVALON study was a randomized, multicenter trial to assess the efficacy and safety of
coadministered amlodipine and atorvastatin in patients with hypertension and dyslipidemia …

Single‐pill amlodipine besylate/atorvastatin calcium (Caduet®, Pfizer Inc, NY, USA) is the
first therapy aimed at the simultaneous treatment of hypertension (HTN) and dyslipidaemia …

Hypertension and dyslipidemia are important risk factors for cardiovascular disease.
However, the clinical outcomes of fixed‐dose combination (FDC) versus free‐equivalent …

Background Hypertension and hypercholesterolemia are important risk factors for
cardiovascular disease, and treatment with fixed‐dose combination (FDC) regimens is …

Guidelines stress the importance of the simultaneous management of multiple
cardiovascular risk factors. This can in part be achieved by coadministration of lipid …

The Gemini Study was a 14‐week, open‐label, noncomparative, office‐based, multicenter
trial to evaluate single‐pill therapy in the treatment of concomitant hypertension and …

Amlodipine/atorvastatin combination therapy has been demonstrated to be an effective
approach for the management of concomitant hypertension (HTN) and dyslipidemia (DYS) …

Patients with hypertension (HTN) and dyslipidemia (DYS) have increased risk for
cardiovascular disease (CVD). The presence of increasing numbers of CV risk factors has a …